The 'obesity paradox' refers to the fact that obese patients have better outcomes than normal weight patients. This has been observed in multiple cardiovascular conditions, but evidence for obesity paradox in pulmonary hypertension (PH) remains sparse. METHODS: We categorized 267 patients from the National Institute of Health-PH registry into five groups based on body mass index (BMI): underweight, normal weight, overweight, obese and morbidly obese. Mortality was compared in BMI groups using the χ 2 statistic. Five-year probability of death using the PH connection (PHC) risk equation was calculated, and the model was compared with BMI groups using Cox proportional hazards regression and Kaplan-Meier (KM) survival curves. RESULTS: Patients had a median age of 39 years (interquartile range 30-50 years), a median BMI of 23.4 kg m −2 (21.0-26.8 kg m − 2 ) and an overall mortality at 5 years of 50.2%. We found a U-shaped relationship between survival and 1-year mortality with the best 1-year survival in overweight patients. KM curves showed the best survival in the overweight, followed by obese and morbidly obese patients, and the worst survival in normal weight and underweight patients (log-rank P = 0.0008). In a Cox proportional hazards analysis, increasing BMI was a highly significant predictor of improved survival even after adjustment for the PHC risk equation with a hazard ratio for death of 0.921 per kg m − 2 (95% confidence interval: 0.886-0.954) (P o0.0001). CONCLUSION: We observed that the best survival was in the overweight patients, making this more of an 'overweight paradox' than an 'obesity paradox'. This has implications for risk stratification and prognosis in group 1 PH patients.
INTRODUCTION
Obesity is one of the leading cardiovascular (CV) risk factors associated with increased morbidity and mortality. 1, 2 Numerous studies have demonstrated obesity as an independent CV risk factor that contributes significantly to the development of heart failure (HF), coronary artery disease, disordered breathing, pulmonary hypertension (PH) and overall survival. [3] [4] [5] [6] Despite this amplification of CV risk associated with obesity, there is an unexpected survival advantage of obese patients in comparison with their normal-to-low body mass index (BMI) counterparts if there is established CV disease (CVD). 7, 8 This surprising observation of attenuated CV mortality among obese and overweight patients has been referred to as the 'obesity paradox', and was first described by Horwich et al. 9 in a cohort of HF patients. The phenomenon of the obesity paradox has since then been described in a wide range of chronic CV conditions including PH. [10] [11] [12] [13] [14] The evidence for obesity paradox in PH is considerably sparse and its validity hotly debated, as evidenced by the numerous editorials on the topic. [15] [16] [17] [18] [19] Furthermore, obesity paradox appears to be confined to certain subtypes of HF. Given the heterogeneity of PH conditions and the global epidemic of obesity, we sought to investigate the association of obesity and mortality in patients with group 1 PH from the National Institute of Health (NIH)-PH registry.
MATERIALS AND METHODS
The NIH established one of the first large registries of PPH patients (all idiopathic PAH, familial PAH and anorexigen-associated) with the specific aim of characterizing demographic, clinical and laboratory findings of patients at the time of diagnosis, as well as determining the natural history of the disease with medical interventions. The methodology and enrollment have previously been published including the risk equation for predicting 5-year survival probability. 20 We used the publicly available de-identified registry data set to investigate the relationship of obesity and survival in group 1 PH patients. 21 This may be accessed at https://biolincc. nhlbi.nih.gov/studies/pphreg. Briefly, patients were enrolled into the registry from 32 medical centers throughout the United States. PH was defined as a mean pulmonary arterial pressure of 425 mm Hg at rest or 30 mm Hg with exercise at the time of hemodynamic assessment with cardiac catheterization. Patients were included in the study after the following secondary causes of PH were excluded: PH within the first year of life, congenital abnormalities of the heart, lungs or diaphragm, pulmonary thromboembolic disease, sickle cell anemia, history of intravenous drug abuse, obstructive lung disease, interstitial lung disease, arterial hypoxemia, collagen vascular disease, parasitic disease affecting the lungs, pulmonary artery or valve stenosis, or pulmonary venous hypertension.
Study design and outcomes
To evaluate the relationship between obesity and the clinical outcomes in the NIH PH database, we analyzed patients who had the necessary invasive hemodynamic data to determine the pulmonary hypertension connection (PHC) risk equation (mean right atrial pressure, mean pulmonary artery pressure and cardiac index) and the clinical variables for the calculation of BMI. Patients were followed for 5 years, and time to death was reported within 5 years of enrollment. The 5-year probability of survival was calculated as a number between 0 and 1 using the PHC risk equation based on the mean pulmonary arterial pressure, mean right atrial pressure and cardiac index. The calculated PHC 5-year survival probability, BMI and pulmonary artery systolic pressure were then evaluated using a multi- ) and morbidly obese (⩾35.0 kg m −2 ). We also used tertiles of obesity to analyze the interaction of obesity and the probability of survival during the study period.
Statistical analysis
Statistical analysis was conducted using SAS 9.4 (SAS Institute, Cary, NC, USA). Analyses of categorical variables were conducted using the χ 2 test. The χ 2 and Fisher's exact tests were used to compare categorical variables. The Wilcoxon's rank-sum test was used to test for differences in continuous variables. Categorical variables are presented as frequencies with percentages, whereas continuous variables are described using medians and interquartile ranges (IQRs). Survival analysis and Kaplan-Meier plots are used to show differences in adverse events between groups with stratification based on key predictor variables. The log-rank test was used to compare differences between groups in this survival analysis. Multivariable Cox proportional hazards regression and multivariable logistic regression were used to model associations of BMI categories with mortality during follow-up. An α-value of 0.05 was used for statistical significance.
RESULTS
Among the 310 patients in the registry, 267 patients 18 years of age or older with complete data for determination of BMI were included in the analysis. The distribution of BMI is shown in Figure 1 . This shows a normal distribution centered around 22 kg m . Five BMI groups were generated based on typically used cutoffs for BMI indicating underweight, normal, overweight, obese and morbidly obese. 22 The number of patients in these five groups was 28, 141, 71, 19 and 8, respectively. Patient characteristics based on these categories for BMI are shown in Table 1 . Age, gender and race were similar across quintiles. Except for cardiac index, for which patients in the lowest BMI group had a slightly higher cardiac index, all other hemodynamic parameters were similar across quartiles.
The differences in survival among these groups for death at 1, 3 and 5 years of follow-up are shown in Figure 2a . The overall rates of death (in the entire patient cohort) at 1, 3 and 5 years of followup were 29.2%, 46.0% and 50.2%, respectively. As shown in the figure, the group with the lowest rate of death at all time points was the overweight group (P = 0.009), and rates of death were also lower in obese and morbidly obese patients compared with patients having either normal weight or underweight patients based on BMI.
The relationship between 1-year mortality and BMI was U-shaped, as shown in Figure 2b . The U-shaped relationship for mortality still was present 3 and 5 years, but the greater death rates for the underweight and normal weight groups versus obese and morbidly obese patients became more apparent at these time points (P = 0.009). With respect to obese and morbidly obese patients, by 3 years, Figure 2a shows that mortality in patients with BMI430 kg m −2 was clearly lower compared with patients having normal weight, and patients with BMI430 kg m −2 had lower mortality rates than patients with a normal weight at all time points (Figure 2a ). It is remarkable that patients who were underweight by BMI had similar mortality rates at all time points compared with patients having a normal weight based on BMI.
Considering that mortality rates were similar in underweight and normal weight groups, and mortality rates were also similar between obese and morbidly obese groups, Kaplan-Meier survival curves were constructed with underweight and normal patients grouped together and with obese and morbidly obese patients grouped together in Figure 3 . The survival curves show a clear separation of survival in the three groups. Survival is best at all time points in the overweight group, consistent with the U-shaped relationship between BMI and survival noted in Figure 2 ; however, survival was much worse in the normal weight/underweight group versus the obese/morbidly obese group. Although normal weight and underweight patients are grouped together for clarity of presentation, there was very little difference in the survival curves between the underweight and normal weight groups when survival curves were plotted for all five groups, and the same held true for the obese and morbidly obese groups.
Although mortality was lowest for the overweight group during the first year, the differences in mortality between the overweight and obese/morbidly obese patients became less prominent with longer follow-up and were significantly lower than those in the normal weight and underweight groups. As a result, we constructed a Cox proportional hazards model for mortality based on the BMI as a continuous variable and adjustment for the PHC risk equation. BMI was a highly significant predictor of mortality even after adjustment for the PHC risk equation with a hazard ratio of 0.921 per kg m −2 (95% confidence interval: 0.886-0.954) (P o 0.0001). Age (P = 0.82) or gender (P = 0.50) were not significant in the multivariable model with BMI and the PHC risk equation, and they did not alter the significance of BMI or the PHC risk equation for mortality in this model Furthermore, the χ 2 value for BMI was about half that of the PHC risk equation, indicating that BMI has a strong influence on mortality even after adjustment for the PHC risk equation.
DISCUSSION
The present study of the NIH primary PH database aimed to evaluate the association between BMI and survival probability among patients with group 1 PH. The main finding of our study was that higher BMI (overweight status) was independently associated with improved probability of survival during the 5-year follow-up of the study, thus highlighting the existence of the 'overweight paradox' in group 1 PH patients. We also found that BMI had a curvilinear relationship with the probability of survival in patients with group 1 PH. There was a 'U-shaped' relationship of BMI and the risk of mortality in this cohort of PH patients even after adjustment for the PHC, age and gender. Mortality rates even in obese and morbidly obese patients were lower compared with both normal weight patients and underweight patients, but these Obesity paradox in group 1 pulmonary hypertension S Mazimba et al patients had a higher mortality than patients in the overweight category.
These findings mirror previously published studies in HF with respect to BMI and mortality. [23] [24] [25] Cardiac cachexia, an important indicator of CV frailty, is characterized by a declining overall function that may serve as a surrogate maker for advanced disease status and therefore explain the observed increased mortality relative to the overweight/obese patients. 26 At the same time, the very obese patients (BMI435 kg m − 2 ) in HF studies do not seem to have favorable survival. 18 ,27 Interestingly, we did not find statistically significant differences across the BMI categories with respect to maximal workload oxygen consumption (VO 2 workload). We used VO 2 workload in this analysis as a surrogate maker for cardiopulmonary fitness, which has been shown to modify the obesity paradox in HF studies. ) had a survival advantage and were more likely to present in functional class III or IV or with greater hemodynamic impairment than nonobese patients. 29 Our analysis of the relationship of hemodynamic indices and the BMI strata differ considerably from that reported in the REVEAL registry. In this study, the only hemodynamic variable that was statistically different across the BMI strata was the cardiac index, which was notably lower in patients with normal BMI. Overall, there are other remarkable differences between the NIH PH and REVEAL databases that go beyond the eras during which the two registries were conducted. 30 The REVEAL registry included patients with pulmonary capillary pressures in the ranges of 16-18 mm Hg. The majority of such patients were older, had more severe hemodynamic impairments and were more likely to be obese than patients with a PCWP ⩽ 15 mm Hg. 31 In addition, a considerable number of patients (37%) in the REVEAL registry had COPD and sleep apnea, 32 both conditions that met exclusion criteria in NIH PH database.
Our study further extends the observation of obesity paradox among group 1 PH patients, especially with respect to the intriguing curvilinear relationship of BMI and survival. There is a paucity of literature on the relationship between obesity and mortality in PH patients. Scientific evidence is even sparser on the question of whether the obesity paradox, across the spectrum of the current WHO PH classifications, still remains a valid phenomenon. For instance, interesting evidence has emerged to suggest that the obesity paradox may not be uniformly applicable to all subtypes of HF patients. Along the same lines, a recent study by Shah et al. 33 demonstrated that the obesity paradox was confined to a subset of older patients, those with lower ejection fraction and those without diabetes mellitus. Furthermore, a study by Zamora et al. 34 reported that over the long-term follow-up of ischemic and non-ischemic HF patients, the obesity paradox was only observed in patients with non-ischemic HF. A study by Kuwat et al., 35 evaluating patients with idiopathic PAH on vasodilator therapies, failed to show an association between obesity and mortality. On the other hand, Benza et al. 36 demonstrated the modulating effects of obesity on mortality in patients with PAH treated with subcutaneous treprostinil. These patients were observed to have a statistically significant survival advantage compared with their non-obese counterparts, a finding that was also mirrored by Zafir et al., 13 when they showed that obesity had salutary effects on mortality in both pre-and postcapillary PH. 13 The obesity-mortality association was observed in their study despite the disparate PH groups, with fundamentally varied pathophysiological processes; our findings differ remarkably from the aforementioned study by Zafir et al. 13 (who included both preand postcapillary PH) in that patients in the current study were rigorously evaluated and all secondary causes of PH were excluded and could therefore be appropriately classified into group 1 PH under the current PH guidelines.
The biological mechanisms underlying the obesity paradox in many CV conditions have been difficult to examine in experimental studies. However, there are some putative physiological mechanisms that have been proposed to explain the observed Abbreviations: BMI, body mass index; MAP, mean arterial pressure; NYHA, New York Heart Association; PAC, pulmonary arterial capacitance; PADP, pulmonary artery diastolic pressure; PAP, pulmonary artery pressure; PASP, pulmonary artery systolic pressure; PCWP, pulmonary capillary wedge pressure; PPP, proportional pulse pressure; PVR, pulmonary vascular resistance; RAP, right atrial pressure; TPG, transpulmonary pressure gradient; RVSWI, right ventricular stroke work index.
Obesity paradox in group 1 pulmonary hypertension S Mazimba et al association between obesity and CV mortality. For example, obese patients are considered to have greater 'metabolic reserve' and may also stand to benefit more from the protective effects of lipoproteins through the binding of endotoxins. Taken together, such mechanisms have been speculated to lead to a favorable interaction of obesity and mortality in patients with established CVD. [37] [38] [39] A recent study reported that the obesity paradox in a PH animal model could, in part, be explained by an overexpression of the sympathetic nervous activity that then differentially modulates the pulmonary vascular tone, thereby constraining the ill effects of the severity of PH. 40 In the same vein, some authors have speculated that ischemic preconditioning, from intermittent exposure of chronic hypoxemia, and increased sympathetic nervous activity, in obesity may paradoxically confer a survival advantage. 41 Despite the above mechanistic propositions for the obesity paradox, there remains no real consensus on its validity. Some opponents of the obesity paradox contend that it is merely a scientific 'artifact' arguing that the obesity paradox can be explained by variables such as lag time bias (from early presentation of obese patients), overreliance on the BMI metric (which is an imperfect measure of total body adiposity), as well as the clustering of unmeasured confounders associated with the phenotype of obesity. 42, 43 Nonetheless, other studies using percent body fat and waist circumference matrices as measures of adiposity have reported the existence of obesity paradox in CVD. 8, [44] [45] [46] [47] [48] Limitations Among the limitations of this study were that patients in the NIH PH database were somewhat younger compared with more recent PH registries. 30 Second, the prognosis and survival outlook of PH patients during the period of the study was dismal compared with the current era, in part, due to the wide availability of pulmonary vasodilator therapies coupled with widespread information of PH necessitating early referral. 49, 50 Third, there have been several adaptations of the PH guidelines including several nomenclatural and classification changes, since the conclusion of the registry. 51 Fourth, we used BMI as a measure of obesity even though this metric is an imperfect measure of total body adiposity in contrast to other metrics such as percent body fat and waist circumference measurements. 52, 53 Finally, the number of patients in the underweight and obese groups was relatively small (18 and 27, respectively). These limitations are offset by the strengths of the current study, including the rigorous screening for group 1 PH, multicenter enrollment, long-term follow-up (5 years) and adjustment for the PHC risk equation, derived in the modern era of pulmonary vasodilator therapies. 54 
CONCLUSIONS
We observed that the best survival was in the overweight patients, making this more of an 'overweight paradox' than an 'obesity paradox'. Furthermore, obese and morbidly obese patients were found to have better survival than patients in the normal weight and underweight categories. These findings have important implications for risk stratification and prognosis in group 1 PH patients.
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The authors declare no conflict of interest. Figure 2 . BMI and survival. As shown in (a), the best survival at all time points is in the overweight group, and survival improves with increasing BMI, particularly at the late time point. In (b), the U-shaped relationship between BMI and survival is apparent. Figure 3 . Kaplan-Meier survival curves for body mass index categories. Kaplan-Meier curves are shown for patients with the five BMI categories showing incremental survival benefit with increasing BMI quartiles (log-rank P = 0.008).
